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Abstract: Adenosine deaminase deficiency (ADA) is a rare, inherited disorder of purine 
metabolism characterized by immunodeficiency, failure to thrive and metabolic abnormalities. 
A lack of the enzyme ADA allows accumulation of toxic metabolites causing defects of both 
cell mediated and humoral immunity leading to ADA severe combined immune deficiency 
(SCID), a condition that can be fatal in early infancy if left untreated. Hematopoietic stem 
cell transplant is curative but is dependent on a good donor match. Other therapeutic options 
include enzyme replacement therapy (ERT) with pegademase bovine (PEG-ADA) and more 
recently gene therapy. PEG-ADA has been used in over 150 patients worldwide and has allowed 
stabilization of patients awaiting more definitive treatment with hematopoietic stem cell trans-
plant. It affords both metabolic detoxification and protective immune function with patients 
remaining clinically well, but immune reconstitution is often suboptimal and may not be long 
lived. We discuss the pharmacokinetics, immune reconstitution, effects on systemic disease and 
side effects of treatment with PEG-ADA. We also review the long-term outcome of patients 
receiving ERT and discuss the role of PEG-ADA in the management of infants and children 
with ADA-SCID, alongside other therapeutic options.
Keywords: adenosine deaminase deficiency, PEG-ADA, enzyme replacement therapy, severe 
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Introduction
Adenosine deaminase (ADA) deficiency is a rare inherited disorder of purine 
metabolism characterized by severe and recurrent infection, failure to thrive and meta-
bolic abnormalities. Absence of the enzyme ADA allows accumulation of toxic 
metabolites resulting in a complete or partial deficiency of both cell-mediated and 
humoral immunity. ADA severe combined immune deficiency (SCID) is fatal within 
the first months of life if left untreated. Hematopoietic stem cell transplant is cura-
tive but dependent on a good donor match. Other therapeutic options include enzyme 
replacement therapy (ERT) with pegademase bovine (hereon referred to as PEG-ADA) 
and more recently, gene therapy. PEG-ADA was first used to treat ADA deficiency 
in 1986 and to date more than 150 patients worldwide have received this treatment. It 
is well tolerated and can restore immune function to protective levels but long-term 
follow up suggests that immune recovery is incomplete. The precise role of PEG-
ADA alongside other treatment options is still to be determined but to date it has 
allowed stabilization of patients awaiting more definitive treatment and clinical 
well-being in individuals treated for more prolonged periods.Biologics: Targets & Therapy 2009:3 350
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In 1972 Giblett et al1 described the absence of the enzyme 
ADA in erythrocytes in two patients with combined immune 
deficiency. Subsequently, with greater awareness, more 
patients with similar findings were reported and the clinical 
and immunological phenotype of ADA deficiency was 
established. Patients can be divided into four phenotypes; 
ADA SCID, delayed onset ADA deficiency, late onset 
ADA deficiency and partial ADA deficiency. The largest 
number of patients (∼85% to 90%) present as ADA SCID 
and represent the most severe form of immunodeficiency; 
delayed onset presentation accounts for 10% to 15% of cases 
and late (or adult) onset deficiency has been identified in a 
handful of individuals. Partial deficiency can be an incidental 
finding in a healthy individual where immune function is 
normal but ADA expression is abnormal in erythrocytes and 
is again extremely rare. The incidence of ADA deficiency 
is estimated to be between 1 in 200,000 and 1 in 1,000,000 
births2 and accounts for around 15% to 20% of all SCID cases, 
although the true incidence of the disease is undetermined 
and may be higher in specific ethnic populations worldwide.
Metabolic abnormalities
ADA is a predominantly cytoplasmic enzyme found in all 
tissues of the body where it plays an important role in the 
recycling of adenosine after DNA breakdown and specifically 
catalyzes the deamination of deoxyadenosine (dAdo) and 
adenosine (Ado) to deoxyinosine and inosine respectively.3 
An extracellular form of the enzyme (ecto-ADA) is found 
on the surface of many cell types where it binds the cell 
surface protein CD26 and specific adenosine receptors. 
Although ubiquitously expressed in keeping with its role as 
a ‘housekeeping’ enzyme, ADA expression levels are highest 
in the thymus and in lymphocytes where levels are 800- to 
1000-fold higher than in erythrocytes.4 High levels are also 
found in the foregut and brain. The lack of ADA results in a 
number of metabolic derangements which ultimately lead to 
the accumulation of toxic substrates in both intra- and extra-
cellular compartments. The high levels of ADA activity in the 
thymus may be a direct consequence of the high level of cell 
turnover during thymic lymphocyte selection and the require-
ment for rapid and extensive DNA synthesis. Despite its 
importance for many organ systems, it is clear that the lack 
of ADA has its most profound manifestations in the immune 
system and in lymphocyte development and function.
Lack of ADA activity leads to the accumulation of Ado 
and dAdo. Cells compensate for rising levels of dAdo by 
converting intracellular dAdo to deoxyadenosine triphos-
phate (dATP) through the action of deoxycytidine kinase 
(dCyd kinase). Increased dAdo levels inactivate the enzyme 
S-adenosyl homocysteine hydrolase (SAHH) leading to the 
accumulation of S-adenosyl homocysteine (AdoHcy) which 
is a potent inhibitor of transmethylation reactions. SAHH 
activity in patients with ADA deficiency is usually 5% of 
normal levels.2
Elevated dATP levels have several toxic effects which 
may all play a role in lymphotoxicity and dATP levels have 
been shown to correlate with clinical severity. It has been 
shown in both ADA-deficient patients and murine models that 
dATP pool expansion leads to inhibition of ribonucelotide 
reductase required for DNA replication and repair5 and in 
induction of apoptosis in immature thymocytes.2 Because 
cells with a high turnover produce more dATP, apoptosis, 
which is the fate of most lymphocytes entering the thymus, 
also increases the dATP pool within the thymus. Limited 
antigen receptor diversity has been demonstrated through 
interference of dATP with terminal deoxynycleotidyl trans-
ferase (TdT)6 and defective signaling pathways may also 
impair lymphocyte function.2 Apoptosis in thymocytes is 
also induced by accumulated extracellular adenosine acting 
through A(2A) adenosine receptors.
Presentation
Children with ADA SCID present within the first months 
of life with failure to thrive, life threatening infections and 
profound lymphopenia. Interstitial pneumonitis is a common 
feature and may be caused by a viral pathogen or commonly 
Pneumocystis jiroveci but may also be an intrinsic manifes-
tation of ADA deficiency. Pulmonary alveolar proteinosis 
(PAP) has been identified radiologically and histologically 
in ADA-deficient patients and is reversible upon treatment 
(Grunebaum et al, Abstract at ESID 2008). Results from 
broncheoalveolar lavage (BAL) undertaken in ADA SCID 
patients with clinical and radiological manifestations of 
pneumonitis revealed a high percentage of children in whom 
no pathogen was identified (Gaspar, unpublished data) again 
suggesting that pulmonary damage in ADA-deficient patients 
is an intrinsic consequence of the disease. Infants may also 
suffer from opportunistic infections in other organ systems, 
diarrhoea and candidiasis. Clinical examination reveals physi-
cal signs usually related to infection and poor growth and the 
absence of lymph nodes and tonsillar tissue due to the lack of 
secondary lymphoid organ development. The thymic shadow 
may be absent or reduced on chest radiography and blood tests 
reveal a profound lymphopenia with greatly reduced numbers 
of T, B and NK cells leading to T-B-NK- SCID phenotype. 
Functional lymphocyte studies unsurprisingly show absent Biologics: Targets & Therapy 2009:3 351
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proliferation in response to mitogen stimulation and lack of 
immunoglobulin production.
Immunodeficiency is the most profound, and in the 
majority of cases first manifestation of ADA deficiency but the 
ubiquitous expression of ADA results in abnormalities in other 
organ systems. Since untreated children invariably have a short 
life expectancy, non-immunological deficits have usually been 
recognized once the immunodeficiency has been corrected by 
bone marrow transplantation. Abnormal neurological find-
ings, without evidence of central nervous system infection, 
such as developmental delay, abnormal muscle tone and 
sensorineural deafness are well described. High levels of ADA 
expression have been reported in brain tissue7 and it is possible 
that high levels of dATP are neurotoxic. Cognitive function 
is adversely affected by the severity of metabolic derange-
ment at diagnosis and a significant inverse correlation has 
been shown between dATP levels at diagnosis and IQ score.8 
Significant behavioral abnormalities are also seen in these 
patients which is not related to the process of transplantation 
as demonstrated by a case-matched study.8 Post mortem 
findings in eight children with ADA deficiency revealed 
non-lymphoid multisystem pathologic changes, mainly renal 
and skeletal.9 Autoimmune phenomena such as idiopathic 
thrombocytopenia and hemolytic anemia are well described.10 
Other rare presenting features include insulin dependent 
diabetes mellitus with atopic dermatitis11 and hepatitis.12
Delayed onset ADA deficiency is the term applied to 
patients who present after the first year of life and is most 
likely related to the specific ADA mutation which in such 
cases results in some residual ADA activity and less severe 
dATP expansion and consequently less profound lympho-
penia and immune function. Such patients present with 
recurrent infection and lymphopenia but rarely infection with 
opportunistic pathogens. Immune dysregulation, autoimmune 
and allergic phenomena and cytopenias may also be a feature 
of this phenotype. A history of recurrent otitis media, upper 
respiratory tract infection or pneumonia is more commonly 
seen and often these children do not require hospitalization 
initially. Misdiagnosis with other conditions such as allergy 
(due to raised eosinophil counts) or antibody deficiency is 
not uncommon.
Early diagnosis is essential to prevent the complications 
of chronic infection and allow normal growth. Lymphocyte 
subsets and functional studies, proliferation studies and 
immunoglobulin levels are important but diagnosis rests on 
the demonstration of absent or very low plasma or erythro-
cyte ADA activity levels. Raised dATP levels and reduced 
SAHH activity in erythrocytes also confirm a diagnosis. 
Genetic testing using mutation analysis is available and 
over 70 different mutations (mostly missense mutations) 
have been identified13 involving the ADA gene on chromo-
some 20q13.11.14 Prenatal diagnosis may be performed by 
either mutation analysis or by measurement of enzymatic 
activity in trophoblasts from chorionic villus sampling or 
amniocentesis.15
Management options
Currently there are three management options to treat ADA 
deficiency: hematopoietic stem cell transplant (HSCT), 
ERT and gene therapy. HSCT is a highly successful and 
curative procedure if a matched related donor is available 
with survival rates of ∼90% but this rate falls to nearer 50% 
survival if a matched unrelated donor or haploidentical 
transplant is undertaken.16 Matched family donor transplants 
can be successfully undertaken without the need for prior 
cytoreductive chemotherapy but transplants from other 
donor sources require the use of a chemotherapy regimen. 
Immune reconstitution post transplant confers adequate 
immunity in terms of lymphocyte numbers and function and 
antibody production. Metabolic correction is also seen and 
although dATP levels are reduced they remain higher than 
in a normal individual (and indeed higher than in patients 
on ERT). HSCT is the treatment option of choice if a well 
matched family donor can be found. However, HSCT does 
not correct the non-immunological manifestations of ADA 
deficiency which again suggests that ADA deficiency is a 
systemic disease.
More recently somatic gene therapy for the correction 
of ADA deficiency has evolved, offering patients another 
treatment option. The procedure involves gammaretroviral 
mediated introduction of the human ADA gene into autolo-
gous bone marrow progenitors and subsequent infusion of 
cells back to the patient following mild nonmyeloablative 
chemotherapy. Preliminary results from clinical trials are 
encouraging with the majority of patients experiencing 
immune reconstitution and metabolic detoxification with 
stable engraftment of transduced hematopoietic cells.17,18 
Importantly there has been little toxicity from the procedure 
and to date all patients have survived. Immune reconstitu-
tion appears to be similar to that seen post transplant. Over 
25 patients have now been treated at four centers worldwide, 
with the most extensive experience in Milan and London. 
The protocols differ between the different sites with respect 
to the specific retroviral constructs used for gene transfer 
and the conditioning protocols used. Although the majority 
of patients have shown improved immune recovery after Biologics: Targets & Therapy 2009:3 352
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gene therapy, the level of reconstitution appears variable and 
seems to be determined by a number of factors including, 
the number of gene corrected progenitor cells re-infused 
into the patients, the ability to harvest sufficient stem cells 
and the degree of thymic reserve at the time of gene therapy. 
The kinetics of immune recovery are also delayed when com-
pared to the T cell reconstitution following gene therapy for 
the X-linked form of SCID. However a number of patients 
show long-term (5 years) complete T cell and humoral 
recovery and have been able to discontinue all prophylactic 
medication and immunoglobulin replacement therapy. These 
pioneering studies suggest that gene therapy can at least in 
principle provide effective immune and metabolic recovery. 
The success of gene therapy is tempered by the potential for 
insertional mutagenesis and leukemic transformation as a 
result of using gammaretroviral vectors.19,20 These compli-
cations have been seen in trials of gene therapy for other 
immunodeficiencies but not so far in ADA gene therapy 
studies. Gene therapy remains an option if well matched 
HSCT donor is not available and is only possible through 
recruitment at specialized academic centers.
Red cell transfusions
Originally enzyme replacement was delivered through eryth-
rocyte transfusions after work by Polmar et al demonstrated 
addition, in vitro, of calf-intestinal ADA or human erythro-
cyte ADA to ADA deficient patients lymphocytes restored 
proliferation after mitogen stimulation.21 Several patients 
were treated with regular transfusions of frozen, irradiated red 
blood cells every 2 to 4 weeks. Initial reports were promis-
ing indicating an improvement not only in clinical status but 
also in immunological function. Children remained free of 
infection for up to 2 years and showed an improvement in 
lymphocyte numbers and function.22,23 Metabolic derange-
ments were also seen to normalize with an increase in ADA 
activity, reduction in adenosine and deoxyadenosine levels 
and a decrease in erythrocyte dATP.23–25 However, these 
improvements proved to be transient and dependent on 
regular transfusions.25 Long-term transfusion therapy car-
ries with it certain risks including iron overload, exposure 
to potential blood borne viral pathogens and the trauma of 
repeated cannulation and time in hospital. These are signifi-
cant risks in immunodeficient children who already spend 
much time in a hospital environment. Bax et al26 reported a 
patient diagnosed in her mid-thirties with ADA deficiency 
who was treated for 9 years with autologous erythrocyte 
encapsulated ADA infusions (after one year of combined 
PEG-ADA injections). The patient was not a candidate for 
HSCT but this treatment proved metabolically and clinically 
effective in this case.
Later studies did not show such a positive outcome with 
regular red blood cell transfusions and in fact, demonstrated 
insufficient metabolic correction to allow for immune 
recovery, although clinical status did often improve.25,27 After 
the introduction of PEG-ADA a comparative study proved 
PEG-ADA to be a superior form of enzyme replacement and 
red cell transfusion was rendered obsolete.27
Enzyme replacement therapy
ERT with PEG-ADA (Adagen®; Enzon Inc; obtained outside 
USA through Orphan Europe) for the treatment of ADA 
deficiency has been available for almost 20 years and has been 
designated an orphan drug. The use of PEG-ADA provides 
another treatment modality for ADA SCID, however unlike 
HSCT or gene therapy it is not a curative therapy but requires 
regular intramuscular administration. Nevertheless, the 
effectiveness of PEG-ADA in correcting metabolic and 
immunological parameters and more importantly in promoting 
clinical well-being in patients, makes it an important option 
in the care of patients. The question remains as to the timing 
and specific role of the three different treatment modalities 
in the treatment of ADA SCID patients and is the subject of 
more detailed discussion below.
PEGylation
PEGylation, a process pioneered in the 1970s, involves the 
covalent attachment of numerous strands of monomethoxy-
polyethylene glycol (PEG) to a molecule, for example an 
enzyme or protein. PEG itself is neither toxic nor immunogenic. 
The attachment of PEG to ADA through lysine residues confers 
several therapeutically beneficial properties to ADA through 
alteration of its physical and chemical properties, mainly due 
to an increase in molecular weight.28,29 The circulating life of 
the compound is prolonged from minutes to days as clearance 
from the circulation is inhibited. Molecules are protected some-
what from cellular uptake, proteolytic attack, renal clearance, 
antibody binding and antigen presentation. PEGylation also 
reduces the immunogenicity of a protein which again helps 
to extend its circulating life.28,29 In theory, if a drug or protein 
remains in the circulation for a longer period then the frequency 
of administration could be reduced thus reducing cost and the 
number of injections a patient requires. In 1986, Hershfield 
et al first used ADA derived from bovine intestine conjugated 
to PEG to treat patients with ADA deficiency.30
Other PEGylated therapies currently used in clinical 
practice  include  PEGASYS®  (Hoffman-La  Roche) Biologics: Targets & Therapy 2009:3 353
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and PEG-Intron® (Schering-Plough/Enzon) which are 
PEGylated alpha-interferons used to treat chronic hepatitis 
B and C and PEGylated L-asparaginase (Oncaspar®; Enzon) 
used for the treatment of acute lymphoblastic leukemia.
The emergence of new variant Creutzfeldt–Jakob disease 
(CJD) has led to concerns over the use of bovine ADA as 
the source of enzyme for PEG-ADA. Bovine ADA is now 
extracted from bovine herds in countries where nvCJD has 
not been identified. There has also been much speculation 
over whether a human recombinant form of ADA may be 
developed.
Kinetics and dosage
PEG-ADA is administered by intramuscular injection once 
or twice weekly. Plasma levels of ADA activity peak 24 to 
48 hours after injection and the half life varies from 3 to 
more than 6 days. The elimination and pharmacokinetics of 
PEG-ADA are variable within the same patient and monitoring 
of plasma ADA activity helps to guide dosage and frequency of 
administration. Reports also suggest that clearance is enhanced 
in younger infants and more severely ill children.2,31 Cellular 
uptake of PEG-ADA is not significant but maintaining plasma 
ADA levels 100-fold normal levels leads to a reduction in 
extracellular Ado and dAdo levels and subsequent normaliza-
tion of intracellular levels16 through maintenance of equilib-
rium between intra- and extracellular compartments.
Since the first patients were treated, the dosing regime has 
evolved and it is now advised that children should start at a 
dose of 60 U/kg/week with biweekly injections until meta-
bolic correction is established (between 1 and 3 months). Once 
patients show clinical improvement and biochemical stabi-
lization they can be maintained on a dose of 30 U/kg/week 
in a single weekly injection,32,33 unpub. It is important when 
monitoring patients to assess their immune function as well 
as metabolic parameters and this should be taken into account 
when considering altering the dose of PEG-ADA.
Dosage should be adjusted according to trough levels 
of plasma ADA activity. Erythrocyte dATP levels can also 
be measured and used to guide treatment. Initial trough 
plasma ADA levels (prior to injection) should be maintained 
at 50–150 µmol/h/mL (normal range 0.4 µmol/h/mL) 
which equates to approximately 4 to 10 times the normal 
erythrocyte ADA activity2 and is required for intial rapid 
detoxification. Once a maintenance dose of 30 U/kg/week 
is established, trough plasma ADA levels can be maintained 
at 25 to 60 µmol/h/mL. Erythrocyte dATP levels decrease 
significantly and are maintained at levels below that seen after 
HSCT. In addition, SAHH activity is seen to normalize.
It is recommended that trough plasma ADA activity levels 
are monitored every 1 to 2 weeks during the first 2 to 3 months 
of treatment, twice a month until 9 months of treatment and 
then monthly until 18 to 24 months on PEG-ADA. Once 
patients are established on an effective maintenance dose then 
plasma ADA levels can be measured every 2 to 4 months 
unless there is a change in clinical status.
Immune reconstitution
Immune reconstitution following treatment with PEG-ADA 
has to date not been followed in a prospective manner and 
therefore formal data are not available. The reasons for this 
are varied but most probably due to the rarity of the condi-
tion and the fact that any one center treats only a handful of 
patients. The data cited below are therefore taken from ret-
rospective and single-center studies which stretch back over 
the last 20 years. Overall, it is clear that immune recovery 
is very variable, the reasons for which may be associated 
with the underlying clinical condition of the child, the age 
at which treatment is started and also the level of residual 
thymic activity at the time of PEG-ADA initiation. Up to 
20% of patients receiving therapy show no response.2,33 In 
the majority of cases, full immune recovery is seen in the 
short term but is followed by waning T cell numbers.10 In 
terms of humoral immunity, continued immunoglobulin 
replacement is required in up to 50% of those treated with 
long-term PEG-ADA.16 It is also important to document 
that, from the retrospective reports available and from com-
munication with physicians treating patients, despite low 
T cell reconstitution and lack of humoral recovery, clinical 
well being is maintained and children who have been treated 
for many years remain clinically well, free of infection, with 
normal growth parameters.
Immune recovery is evidenced initially by a rise in B cell 
numbers within a few weeks of starting treatment and is then 
followed by a rise in T cell count which may take a number 
of months to occur. Symptoms of immune dysregulation such 
as hemolytic anemia and immune thrombocytopenia can be 
seen during this period and may be related to dysregulated 
cellular and humoral recovery. Immature T lymphocytes 
appear first and account for the rise in T cell numbers. Prolif-
erative responses can be detected once mature T lymphocytes 
develop demonstrating that ADA-deficient thymic progeni-
tors are able to mature into functional T lymphocytes in the 
presence of metabolic correction.31 Initially these responses 
are IL-2 dependent and later become IL-2 independent.31 
Long-term outcome data suggest that mitogen responses 
often fluctuate within the same patient over time32 with Biologics: Targets & Therapy 2009:3 354
Booth and Gaspar Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
normal responses evident in only about 50% of patients. 
Specific antigen responses return in the majority of children 
over a similar time frame to that seen post HSCT.
Antibody responses to immunization with bacterio-
phage ΦX174 are useful as this is an antigen not present 
in replacement immunoglobulin.34 Serum immunoglobulin 
levels generally rise after a few months of treatment but this 
is not uniform and as mentioned previously, up to half of chil-
dren receiving PEG-ADA require ongoing immunoglobulin 
replacement. NK cell activity has been documented in one 
patient as returning after 5 months.31
Initial reports of short-term follow up of patients treated 
with PEG-ADA were promising, demonstrating partial but 
protective immune recovery and clinical improvement with a 
reduction in the number and severity of infections. However, 
even shortly after clinical trials began it was evident that 
immune reconstitution faltered after a few years of treatment 
despite maintaining stable plasma ADA levels conducive 
with immune recovery.32
Deaths have been reported within the first 6 months of 
treatment (mainly in the first month) but it is likely that this 
represented mortality due to infection at diagnosis and was 
not related to PEG-ADA treatment.
Around 30% of those treated with PEG-ADA have a 
delayed onset phenoytype.16 These patients are particular, 
often suffering the effects of chronic infection coupled 
with some residual immune function which can complicate 
engraftment following HSCT. One case report describes a 
14-month-old girl with delayed onset ADA deficiency who 
responded well to PEG-ADA therapy showing almost full 
immune recovery but went on to develop inhibitory IgG 
anti-ADA antibodies which resulted in reaccumulation 
of toxic metabolites and subsequent reversal of immune 
reconstitution.4 Older patients have been treated successfully 
and are able to lead a normal life, including schooling.32,35
Long-term outcome in patients 
treated with PEG-ADA
Data on long-term outcome in patients with ADA deficiency 
treated with PEG-ADA has been published by several 
groups.16,36,37 Chan et al37 published a retrospective review 
of five patients treated in North America with follow up 
data from 1995 to 2002. The patients were mostly typical 
ADA-SCID patients with early presentation (one late onset 
patient) who had received PEG-ADA for 5 to 15 years. Their 
clinical course over this time was good with little in the 
way of recurrent or severe infections, although any immune 
reconstitution associated with treatment declined over time. 
The majority of  children also received other forms of  treatment 
including HSCT and gene therapy. Absolute lymphocyte 
counts (ALC) remained below the normal range despite 
improving from baseline. ALC peaked between 1 to 3 years on 
PEG-ADA at 250 to 1480 cells/mm3 but fell after 5 to 12 years 
of therapy to 12 to 500 cells/mm3. It was noted that the 
changing CD4:CD8 ratio seen with increasing age was main-
tained. B cell numbers showed an improvement that was 
not sustained, peaking at 60 to 1270 cells/mm3 then falling 
to subnormal range. NK cells were also monitored in most 
patients and reached normal numbers (120 to 2400 cells/mm3) 
before falling to 30 to 230 cells/mm3. Proliferative responses 
normalized in some patients after an average of 4 months of 
treatment before declining over time. Immunglobulin produc-
tion was difficult to assess as patients received supplemental 
immunoglobulin. It was postulated that a reversal of immune 
recovery may be related to a reduction in thymopoeisis which 
naturally occurs as a child grows older. Low levels of ADA 
in the thymus are known to be toxic to lymphocyte precursors 
entering the thymus38 and it may be that irreversible dam-
age is already present in the thymus before any treatment is 
started (as toxicity is present in utero, and damage may begin 
before birth), and severely affects the potential for lymphocyte 
development and proliferation.
Malacarne et al36 explored thymic output and immune 
reconstitution in five patients (ages 5 to 9 years) with ADA 
SCID treated with PEG-ADA for 5 to 8 years. B cell and 
T cell numbers again increased 5 to 14 months following 
initiation of treatment but remained low in comparison to 
normal controls. Patient responses to PHA (mitogen) stimula-
tion increased but were variable even within the same patient. 
Four of the five patients developed specific antibodies after 
immunization with tetanus and showed an increase in serum 
immunoglobulin levels. Normal T cell development and 
thymic output were measured through T cell receptor exci-
sion circles (TRECS) and these proved to be consistently low 
compared with healthy age matched controls again suggesting 
a compromise in thymic function. Accelerated apoptosis was 
also demonstrated in patients T lymphocytes. B cell repertoire 
was examined and found to be restricted but it is not clear 
if this relates to an intrinsic B cell problem or secondary to 
defects in the T cell compartment. Patients remained clinically 
well on long-term therapy with PEG-ADA.
A European survey of patients receiving PEG-ADA 
therapy was undertaken in 2005 (involving the ESID and 
EBMT Inborn Errors Working Parties) and preliminary data 
were published in 2007.16 Data gathered from 42 patients 
based in several European centers showed that PEG-ADA was Biologics: Targets & Therapy 2009:3 355
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started in the first 6 months of life in over half of the patients 
(n = 27). Two thirds of patients received PEG-ADA only and 
the remainder progressed to HSCT or gene therapy. Four 
reported deaths were infection related (CMV viremia, RSV 
infection, encephalitis and pneumonitis) and were unlikely 
to be related to PEG-ADA. As previously reported, immune 
recovery was variable with T lymphocyte numbers below 
the normal range after one year of treatment (mean CD3+ 
count: 460 cells/mm3). Immunoglobulin levels improved to 
the extent that 40% of patients received immunoglobulin 
replacement after one year. Overall survival in this cohort 
was 85% for children who received PEG-ADA alone (n = 26). 
Survival for those who went onto receive HSCT was 70% 
and 100% for those progressing to gene therapy.
At present the long-term consequences of PEG-ADA 
therapy are unknown but it is clear that immune recovery 
especially in the T cell compartment is below normal levels 
and in some patients runs at levels that are of concern for 
opportunistic infection. The reasons for this have not been 
determined but reduced thymic function either at the onset of 
therapy or over the course of therapy may play an important 
role. The majority of patients have remained clinically well 
without experiencing major infective problems but a number of 
case reports suggest that in certain patients, ongoing low T cell 
numbers has led to significant problems. One boy developed 
Hodgkin’s lymphoma after 13 years of treatment,10 another 
developed Burkitt’s lymphoma again after 13 years of treat-
ment39 and another child developed EBV positive malignant 
brain lymphoma after 10 years of treatment.40 It is likely 
that such lymphoproliferative diseases arise due to reduced 
immune surveillance. Further data gathering is necessary to 
determine overall outcome of patients on long-term therapy.
Effects of PEG-ADA on systemic 
disease
The effects of PEG-ADA on the metabolic disturbances and 
immune reconstitution seen in ADA deficiency have been 
well described but its effect on systemic manifestations remain 
unclear. In a number of major centers, children with ADA defi-
ciency proceed to HSCT when an appropriate donor becomes 
available and PEG-ADA treatment is discontinued and there-
fore long-term systemic outcome data are lacking. In those 
patients that have remained on long-term ERT, there are no 
formal data on the outcome of systemic pathology. Certainly, 
the cognitive and behavioral abnormalities and sensorineural 
deafness described in ADA-deficient patients are not affected 
by metabolic correction and persist after transplantation and 
these are now well documented but no such data exists for 
patients on PEG-ADA. This is perhaps because no individual 
center has a sufficiently large cohort on long-term enzyme 
replacement to perform such a study and because such studies 
especially on behavioral function are difficult to perform across 
a number of different countries and continents.
Some information may be inferred from murine studies. 
ADA-deficient mice exhibit severe pulmonary insufficiency 
in addition to combined immunodeficiency, renal abnor-
malities, hepatocellular degeneration and failure to thrive.12,41 
Mice die before 3 weeks of age from respiratory disease. 
Pulmonary pathology appears to be a primary consequence 
of ADA deficiency and not due to infectious damage12 and 
has been well characterized in the mouse model. Abnormal 
adenosine signaling leads to a developmental defect in alveo-
genesis resulting in enlarged alveolar airways and severe 
lung inflammation. This process appears to be separate to the 
immune consequences of ADA deficiency which are due to 
cytotoxicity of deoxyadenosine and metabolic derangements. 
Blackburn et al42 demonstrated that a relatively ‘low dose’ of 
PEG-ADA was sufficient to prevent the pulmonary pheno-
type but resulted in no change in immunodeficiency. Reduced 
levels of dATP were noted in the lungs and erythrocytes with 
‘low dose’ replacement with an improvement in the clinical 
phenotype and resulted in significantly improved survival of 
treated mice. When mice received ‘high dose’ enzyme replace-
ment a reduction in the metabolic disturbance in the thymus 
and spleen was seen and immune function improved.
There is a case report of a neonate presenting with hepa-
titis and prolonged hyperbilirubinemia who subsequently 
developed immune deficiency and was diagnosed with ADA 
deficiency.12 After commencing ERT, liver dysfunction 
improved and was followed shortly after by improvement 
in lymphocyte count. These data suggest that PEG-ADA, 
through its ability to rapidly detoxify the metabolic conse-
quences of ADA deficiency, is able to reverse a number of 
the clinical pathologies.
Side effects
To date, no toxic or hypersensitivity reactions have been 
reported with Adagen®. Headache and pain at the injection 
site were reported adverse effects during the clinical trial. 
After approval by the FDA several other side effects have 
been reported including hemolytic anemia, autoimmune 
hemolytic anemia, thrombocytopenia and erythema or urti-
caria around the injection site.
The main side effect associated with the use of   
PEG-ADA which will be discussed in more detail is the 
development of anti-ADA antibody. Transient immune Biologics: Targets & Therapy 2009:3 356
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dysregulation can occur during the first few months of treat-
ment as may occur post transplant. One patient described 
developed thrombocytopenia that responded to treatment 
with intravenous immunoglobulin and several others devel-
oped a more persistent hemolytic anemia, in some cases 
associated with intercurrent viral infection or sepsis.2,10 Tran-
sient thrombocytosis (an increased platelet count) has been 
reported by several groups but this has not resulted in any 
clinical sequelae such as thrombosis.16,43 Having reviewed 
data from another two patients being treated with PEG-
ADA at one center, a rise in platelet count was noted after 
PEG-ADA therapy was commenced, but this was within the 
normal range for the majority of treatment. The mechanism 
by which this may occur or be significant is not clear but It 
was speculated that reconstitution of the immune system in 
response to infection may play a role.
The development of specific IgG antibody to bovine 
peptide epitopes of PEG-ADA has been reported by sev-
eral groups and often coincides with an improvement in 
humoral immunity.4,16,33,44 There are no reports of antibody 
formation to PEG itself. It can be detected by ELISA in up 
to 80% of patients on long-term PEG-ADA therapy but is 
clinically insignificant in most. However, in around 10% of 
those treated an inhibitory antibody is produced leading to 
enhanced clearance of PEG-ADA and subsequently a decline 
in metabolic parameters and immune function.4,33,44 Patients 
with delayed or late onset phenotype seem particularly 
susceptible to the development of neutralizing antibody.10 
Development of anti-ADA antibody should be suspected if 
plasma ADA activity consistently falls below 10 µmol/h/mL 
and an ELISA can be performed to confirm its presence.
Chaffee et al44 describe the development of significant 
anti-ADA antibody levels (2 SD mean control group) in 
10 out of 17 patients between 3 and 8 months of treatment. 
Stable plasma ADA activity was maintained in eight patients 
but in two patients was reduced to such a level as to have an 
effect on clinical status and require modification in their man-
agement. One patient responded to twice weekly injections 
rather than weekly. For the other patient PEG-ADA was 
withheld and they were treated with intravenous immuno-
globulin and prednisolone to induce tolerance before recom-
mencing on PEG-ADA. Both human and bovine derived ADA 
were inhibited by these two patients’ antibodies suggesting that 
the antibody recognized a conserved region of the enzyme.
Costs of PEG-ADA
As with many orphan drugs, the cost of PEG-ADA usage 
is high and may prohibit its use in resource poor countries 
or where insurance cover is not readily available. However, 
the cost appears to be in keeping with enzyme replace-
ment for other metabolic conditions and reflects the costs 
of development and production for use in a limited patient 
population.
The role of PEG-ADA
Enzyme replacement therapy with pegylated ADA provides 
metabolic correction and improvement in immune function 
and clinical parameters. However it is not curative and long-
term immune recovery is of concern. The role of PEG-ADA 
has to be set alongside the other treatment options of HSCT 
and gene therapy. At present there is limited formal data on 
the outcome following HSCT after different donor transplants 
and gene therapy trials are confined to ∼20 to 25 patients 
worldwide. Therefore, arriving at any didactic management 
schema is difficult and is often subject to personal preference, 
experience and availability.
Despite these caveats, the consensus suggests that where 
a matched family donor is available the overall success 
rates are very high (90% survival with effective immune 
reconstitution), and thus HSCT is the treatment of choice. 
Even in this donor situation, PEG-ADA may be important 
in stabilizing the child through metabolic detoxification 
prior to transplant. If a matched family donor is unavailable, 
then most centers would start PEG-ADA while initiating an 
unrelated donor search in order to stabilize the child and to 
improve metabolic and immune recovery. Following this, 
there are little formal data to guide how best to proceed since 
the options now include continuation of PEG-ADA, unrelated 
donor transplant or gene therapy. This decision is most likely 
to be dictated by the experience of individual physicians 
and the treatment options available at specific institutions. 
Equally the time for which PEG-ADA should be continued 
is not clear given the poor long-term immune recovery seen 
in patients who nevertheless remain clinically stable. Again, 
this may be resolved once data from large numbers of patients 
on long-term PEG-ADA therapy are available.
PEG-ADA was given as an adjunctive therapy in previ-
ous gene therapy trials45,46 but it is recognized that enzyme 
replacement may blunt the survival advantage of gene cor-
rected cells and therefore patients have been maintained on 
PEG-ADA up until the time of gene therapy, at which point 
it has been discontinued. However, the use of PEG-ADA 
therapy may be important prior to gene therapy in the 
maintenance of a healthy hematopoietic stem cell pool from 
which sufficient cells can be harvested for the transduction 
procedure (Gaspar, unpublished data). Patients who are Biologics: Targets & Therapy 2009:3 357
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on ERT discontinue treatment shortly prior to a transplant 
procedure. There are as yet no reports of patients who have 
successfully undergone transplant or gene therapy restarting 
PEG-ADA even if there are ongoing non-immunological 
abnormalities.
Summary
The development and use of PEG-ADA has provided an 
important alternative option for treatment of patients with 
ADA deficiency. The rapid metabolic detoxification afforded 
by high level enzyme replacement allows clinical stabiliza-
tion of patients and provides longer term treatment options 
when no suitable donor is available. The long-term immune 
recovery on PEG-ADA appears to be suboptimal although 
clinical well-being is maintained in the majority of patients. 
Further long-term data gathered from patients who have 
undergone the different treatment options available for ADA 
deficiency will allow more evidence-based recommendations 
for the role of PEG-ADA in disease management.
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